Correction Notice: Risk of Venous Thromboembolism and Bleeding in Surgical Patients with Obesity Undergoing Enoxaparin Thromboprophylaxis

Overview

This correction notice addresses the omission of the last named author and his affiliation in the published article on venous thromboembolism (VTE) and bleeding risk in surgical patients with obesity receiving enoxaparin thromboprophylaxis. The importance of accurate authorship is emphasized in the context of ongoing research in this critical area.

Background

Obesity is a significant global health issue, affecting over one billion individuals and increasing the risk of venous thromboembolic events (VTE) in surgical patients. Surgical procedures further elevate this risk, necessitating effective thromboprophylaxis strategies. Enoxaparin, a low-molecular-weight heparin, is commonly used for this purpose, but its efficacy and safety in obese populations require careful consideration.

Data Highlights

No numerical data or trial results are presented in the correction notice.

Key Findings

• The correction acknowledges the omission of Juan I. Arcelus as the last named author.
• Obesity is an independent risk factor for VTE, particularly in surgical settings.
• Enoxaparin is widely used for thromboprophylaxis in surgical patients.
• Guidelines recommend risk stratification for VTE prevention in surgical populations.
• Recent studies have explored dosing and monitoring of enoxaparin in obese patients.

Clinical Implications

Accurate authorship is crucial for the integrity of scientific literature, particularly in studies addressing VTE risks in obese surgical patients. Clinicians should remain informed about evolving guidelines and research regarding thromboprophylaxis in this high-risk population.

Conclusion

The correction highlights the importance of proper authorship attribution in medical publications, particularly in critical areas such as VTE risk management in surgical patients with obesity.

Related Resources & Content

1. Juan I. Arcelus, Obesity Surgery, 2024 -- Correction Notice: Risk of Venous Thromboembolism and Bleeding in Surgical Patients with Obesity Undergoing Enoxaparin Thromboprophylaxis
2. Obesity Surgery — Venous Thromboembolism and Bleeding Risk in a Population with Obesity Hospitalized for Surgery and Receiving Enoxaparin for Thromboprophylaxis
3. Obesity Surgery — Evaluation of Anti-factor Xa Levels in Obese Female and Male Patients Following Enoxaparin Administration for Thromboprophylaxis
4. Obesity Surgery — Aiming for Elimination of Thromboembolic Complications Following Bariatric Metabolic Surgery
5. Obesity Surgery — Evaluation of Low Molecular Weight Heparin versus Apixaban for Venous Thromboembolism Prevention Following Laparoscopic Sleeve Gastrectomy
6. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients - PMC
7. 2024 exceptional surveillance of Venous thromboembolism in over 16s (NICE guideline NG89) | Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism | Guidance | NICE
8. The American Society for Metabolic and Bariatric Surgery (ASMBS) updated position statement on perioperative venous thromboembolism prophylaxis in bariatric surgery - PubMed
9. Prevention of perioperative venous thromboembolism: 2024 guidelines from the French Working Group on Perioperative Haemostasis (GIHP) developed in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society of Thrombosis and Haemostasis (SFTH) and the French Society of Vascular Medicine (SFMV) and endorsed by the French Society of Digestive Surgery (SFCD), the French Society of Pharmacology and Therapeutics (SFPT) and INNOVTE (Investigation Network On Venous ThromboEmbolism) network - PubMed
10. Comparison of enoxaparin 40 mg versus 60 mg dosage for venous thromboprophylaxis in patients undergoing bariatric surgery: A randomized controlled trial - PubMed
11. Increasing Enoxaparin Dosing from 30 mg to 40 mg Does Not Affect Bleeding or VTE Risk in Bariatric Surgery Patients - PubMed
12. Evaluation of Anti-Xa Target Attainment with Prophylactic Enoxaparin Dosing Regimens for Venous Thromboembolism Prophylaxis in Morbidly Obese Patients - PubMed
13. Prophylactic Enoxaparin Dosing Using Anti-Factor Xa Levels in Hepatic Surgery Patients: A Pilot Study - Samuel Coster, Ali Shammout, Michael Chaney, Kyra Folkert, Kent Grosh, Saad Shebrain, Gitonga Munene, 2024
14. Cumulative Incidence of Venous Thromboembolic Events In-Hospital, and at 1, 3, 6, and 12 Months After Metabolic and Bariatric Surgery: Systematic Review of 87 Studies and Meta-analysis of 2,731,797 Patients | Obesity Surgery | Springer Nature Link
15. Extended venous thromboembolism prophylaxis after bariatric surgery does not increase postoperative bleeding complications - PubMed
16. Efficacy and safety of direct oral anticoagulants (DOACs) for postoperative thromboprophylaxis in patients after bariatric surgery: a systematic review and meta-analysis - PubMed